Anixa Biosciences shares fall 2.18% intraday after U.S. Patent and Trademark Office to issue patent on ovarian cancer vaccine technology.

Anixa Biosciences, Inc. declined 2.18% in intraday trading, with the company announcing that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2), a promising target for ovarian cancer prevention and treatment.